Protara Therapeutics
Manufacturing · New York, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
345 Park Ave S Fl 3, New York City, New ...Phone Number
(646) 844-0337Website
www.protaratx.comRevenue
$10.1 MillionStock Symbol
TARAIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About Protara Therapeutics
Protara is focused on identifying and optimizing product candidates for patients suffering from rare and specialty diseases where there is a significant unmet need. Protara's current development programs focus on the treatment of rare diseases in structural and connective tissues, as well as rare hepatology/gastrointestinal and metabolic disorders. The Company's lead program, TARA-002, is being developed for the treatment of lymphatic malformations. Protara's second program, IV choline chloride, is a phospholipid substrate replacement therapy in development for the treatment of intestinal failure-associated liver disease.Explore more
Protara Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Protara Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Protara Therapeutics launches new products
Check if Protara Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Protara Therapeutics has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Protara Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Protara Therapeutics had a recent Job posting/layoffs
Earning: See what the market has to say on Protara Therapeutics recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Protara Therapeutics
Check out if Protara Therapeutics is spiking on competitors!
Recommended Actions
Reach out to Masked Content who joined Protara Therapeutics as Masked Content
Find 3 more new buyers
Compare Similar Companies to Protara Therapeutics
Compare insights from companies similar to Protara Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Protara Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Protara Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Protara Therapeutics.
Protara Therapeutics Tech Stack
A closer look at the technologies used by Protara Therapeutics
See more technologies
Most Recent Scoops
Person-Based
Medical Research, Pharmaceuticals, Clinical Operations
Person-Based
Pharmaceuticals, Clinical Operations
Person-Based
Product Development
Person-Based
Earnings, Finance
Person-Based
Medical Research
Protara Therapeutics News & Media
Protara Therapeutics to Host Virtual Investor Webinar to Discuss TARA-002 for Lymphatic Malformations on Tuesday, May 19, 2026
Event will provide an overview of Lymphatic Malformations, the treatment landscape and the TARA-002 clinical programProtara Therapeutics Announces Positive Updated 12-Month Data Demonstrating Durable Responses in the Fully Enrolled BCG-Naïve Cohort of the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in NMIBC
TARA-002 demonstrates 72% complete response rate at any time, 67% complete response rate at the 6-month landmark and 55% complete response rate at the 12-month landmark in BCG-Naïve patientsProtara Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update
The Company intends to submit a Biologics License Application (BLA) for TARA-002 in Lymphatic Malformations (LMs) in 2H 2027Protara Therapeutics to Present Updated, Interim 12-Month Data from the Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients at the American Urological Association Annual Meeting
NEW YORK, April 27, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage biotechnology company developing transformative therapies for the treatment of cancer and rare diseases, today announced that updated, interim data from Cohort A of the ongoing Phase 2 open-label ADVANCED-2 trial evaluating TARA-002 in patients with BCG-Naïve non-muscle invasive bladder cancer (NMIBC) will be featured during a poster session at the upcoming American Urological Association (AU
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Protara Therapeutics
Sign Up For FreeTo access detailed company insights
Protara is focused on identifying and optimizing product candidates for patients suffering from rare and specialty diseases where there is a significant unmet need. Protara's current development programs focus on the treatment of rare diseases in structural and connective tissues, as well as rare hepatology/gastrointestinal and metabolic disorders.... Read More
